Form 4: Compugen Ltd. Executive Trades Ordinary Shares

Zurit Levine, SVP of Business Development at Compugen Ltd., reports transactions involving the acquisition and disposition of ordinary shares and share options.

Summary

• Zurit Levine, SVP of Business Development at Compugen Ltd. (CGEN), executed several transactions on April 10, 2026.
• Levine acquired 1,125 ordinary shares at $0.8292 per share and 2,000 ordinary shares at $1.15 per share.
• These acquisitions were made under a Rule 10b5-1 trading plan adopted on December 23, 2025.
• Levine also disposed of 3,125 ordinary shares at a weighted average price of $2.564 per share, with individual sales ranging from $2.50 to $2.60.
• Following these transactions, Levine beneficially owns 29,375 ordinary shares directly.
• Additionally, Levine holds vested share options for 5,625 ordinary shares with an exercise price of $0.8292 and an expiration date of November 9, 2032.
• Levine also holds vested share options for 56,000 ordinary shares with an exercise price of $1.15 and an expiration date of August 3, 2033.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While it involves executive transactions, the execution under a Rule 10b5-1 plan suggests a planned approach rather than a strong signal of positive or negative sentiment about the company's immediate future.

Positives

• Acquisition of ordinary shares at prices below recent disposal prices, potentially indicating a belief in future price appreciation.
• Transactions executed under a Rule 10b5-1 plan, suggesting pre-planned and potentially non-insider-trading-related activity.
• Significant holdings of vested share options indicate continued long-term incentive alignment with the company's performance.

Negatives

• Disposition of a substantial number of ordinary shares (3,125) at a higher price than recent acquisitions, which could be interpreted as profit-taking.
• The weighted average sale price of $2.564 is significantly higher than the acquisition prices of $0.8292 and $1.15, suggesting a substantial gain on those specific shares.

Risks

• The Rule 10b5-1 plan is subject to the reporting person's continued service to the Issuer, meaning continued employment is a condition for option vesting.
• The specific details of the Rule 10b5-1 plan, including the rationale for the specific acquisition and disposition prices and volumes, are not fully disclosed.

Future Outlook

The filing does not contain explicit forward-looking statements or guidance from the company. However, the continued vesting of share options suggests an expectation of ongoing service and potential future value realization.

Management Comments

• The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The execution of a Rule 10b5-1 plan by an executive like Zurit Levine is a common practice to diversify holdings or manage personal finances while adhering to insider trading regulations. The specific prices and volumes traded will be closely watched by investors for any signals about management's confidence in Compugen's future prospects.

Stakeholder Impact

• Shareholders: The transactions may be interpreted by shareholders as a signal of management's confidence or as profit-taking, depending on the context and future stock performance.
• Employees: The vesting of options for executives like Zurit Levine aligns their financial interests with the company's long-term success, potentially motivating continued performance.
• Creditors: No direct impact on creditors is indicated by this filing.

Next Steps

• Continued monitoring of Zurit Levine's beneficial ownership and any future transactions.
• Observation of the vesting schedule for the remaining share options.
• Analysis of Compugen Ltd.'s overall financial performance and strategic developments to contextualize these insider trades.

Key Dates

Keywords

Form 4, Compugen Ltd., CGEN, Zurit Levine, Ordinary Shares, Share Options, Beneficial Ownership, Rule 10b5-1, Insider Trading, SEC Filing, Executive Transactions